# An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

> **NCT01806298** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 78 (actual)

## Conditions studied

- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** Saizen® solution for injection (referred as Saizen®)

## Key facts

- **NCT ID:** NCT01806298
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806298, "An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01806298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*